Advances in Haematological Pharmacotherapy in 21st Century

Review Article

DOI: 10.1007/s12288-010-0019-1

Cite this article as:
Ghosh, K. & Ghosh, K. Indian J Hematol Blood Transfus (2010) 26: 30. doi:10.1007/s12288-010-0019-1


Last quarter of twentieth century and the first 10 years of 21st century has seen phenomenal development in haematological pharmacotherapy. Tailor made chemotherapeutic agents, vast array of monoclonal antibodies, epigenetic modifiers, growth factors for red cells white cells and platelets, peptidomimetics as growth factors, newer thrombin inhibitors, safer plasma derived protein molecules, recombinant molecules, newer immunomodulators, enzyme replacement therapy and above all a plethora of targetted molecules targeting innumerable pathways involved in cell division, growth, proliferation and apoptosis has given immense number of clinically usable molecules in the hand of modern haematologists to treat diverse hitherto untreatable haematological disorders effectively. In addition many old molecules are finding newer uses in diverse fields, thalidomide as an antiangiogenic molecule is a prime example of this genre. Present overview has tried to capture this rapidly evolving area in a broad canvas without going into details of indications and contraindications of the use of various drugs.



Copyright information

© Indian Society of Haematology & Transfusion Medicine 2010

Authors and Affiliations

  1. 1.National Institute of Immunohaematology (ICMR)MumbaiIndia